Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2012, Pages 184-196

  Bragagni, Marco ^a   Mennini, Natascia ^a   Ghelardini, Carla ^a   Mura, Paola ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DOXORUBICIN; EBEWE; GLUCOSE DERIVATIVE; N PALMITOYLGLUCOSAMINE; NIOSOME; POLY 24 OXYETHYLENE CHOLESTERYL ETHER; POLYMER; SOLULAN C24; SORBITAN PALMITATE; SORBITAN STEARATE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DIALYSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIGHT SCATTERING; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; ROOM TEMPERATURE; THIN LAYER EVAPORATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84857066261     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3230m     Document Type: Article

References (38)

1. Jeanneret LJ. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discovery Today 2008; 13: 1099-1105.
2. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J. Pharm. Pharmaceut. Sci. 2003; 6: 252-273.
3. Patel MM, Goval BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009; 23: 35-58.
4. Kreuter J. Nanoparticulate systems for brain delivery of drugs, Adv. Drug Deliv. Rev. 2001; 47: 65-81.
5. Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood-brain barrier and brain drug delivery. J. Nanosci. Nanotechnol. 2006; 6: 2712-2735.
6. Fang JY, Hong CT, Chiu WT, Wang YY, Effect of liposomes and niosomes on skin permeation of enoxacin. Int. J. Pharm. 2001; 219: 61-72.
7. Attia IA, El-Gizawy SA, Fouda MA, Donia AM. Influence of a Niosomal Formulation on the Oral Bioavailability of Acyclovir in Rabbits AAPS PharmSciTech. 2007; 8: 206-212
8. Yadav JD, Kulkarni PR, Vaidya KA, Shelke GT. Niosomes: a review. J. Pharm. Res. 2011; 4: 632-636.
9. Dufes C, Schatzlein AG, Tetley L, Gray AL, Watson DG, Olivier JC, Uchegbu IF. Niosomes and Polymeric Chitosan Based Vesicles Bearing Transferrin and Glucose Ligands for Drug Targeting. Pharm. Res. 2000; 17: 1250-1258.
10. Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olivier JC, Muller JM. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int. J. Pharm. 2004; 285: 77-85.
11. Stan AC, Casares S, Radu D, Walter GF, Brumeanu TD. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res. 1999; 19: 941-950.
12. Uchegbu IF, Double JA, Turton JA, Florence AT. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span-60) niosomes in the mouse. Pharm. Res. 1995; 12: 1019-1024.
13. Uchegbu IF, Duncan R. Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int. J. Pharm. 1997; 155: 7-17.
14. Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004; 1663: 167-177.
15. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Suiss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim. Biophys. Acta 2006; 1758: 1633-1640.
16. Li X, Ding L, Xu Y, Wang Y, Ping Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int. J. Pharm. 2009; 373: 116-123.
17. Dufes C, Muller JM, Couet W., Olivier JC, Uchegbu IF, Schatzlein AG. Anticancer drug delivery with transferring targeted polymeric vesicles. Pharm. Res. 2004; 21: 101-107.
18. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate80-coated nanoparticles. Pharm. Res. 1999; 16: 1564-1569.
19. Gil ES, Li J, Xiao H, Lowe TL. Quaternary ammonium ß-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules 2009; 10: 505-516
20. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, Imura H, Shigemoto R, Kikuchi H. Distribution of the Glucose Transporters in Human Brain Tumours. Cancer Res. 1992; 52: 3972-3979.
21. Smith TAD. Facilitative glucose transporter expression in human cancer tissue. Br. J. Biomed. Sci. 1999; 56: 285-292.
22. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm. 1998; 172: 33-70.
23. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int. J. Pharm. 1994; 105: 1-6.
24. Hu C, Rhodes DG, Proniosomes: a novel drug carrier preparation. Int. J. Pharm. 1999; 185, 23-35.
25. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in Pglycoprotein-mediated drug resistant tumour cells. Int. J. Pharm. 2007; 329: 94-102.
26. Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS Journal 2007; 9: 371-377.
27. Tavano L, Muzzalupo R, Trombino S, Cassano R, Pingitore A, Picci N. Effect of formulation variables in the in vitro percutaneous permeation of sodium diclofenac from new vesicular systems obtained from Pluronic triblock copolymers. Colloids and Surfaces B: Biointerfaces 2010; 79: 227-234.
28. Bragagni M, Maestrelli F, Mennini N, Ghelardini C, Mura P. Liposomal formulations of prilocaine: effect of complexation with hydroxypropyl-β-cyclodextrin on drug anaesthetic efficacy. J. Lipos. Res. 2010; 20: 315-332.
29. Cielecka-Pionteka J, Jelinskaa A, Zajac M, Sobczak M, Bartold A, Oszczapowicz I. A comparison of the stability of doxorubicin and daunorubicin in solid state. J. Pharm. Biomed. Anal. 2009; 50: 570-579.
30. Harashima H, Hiraiwa T, Ochi Y, Kiwada H. Size-dependent liposome degradation in blood: in vitro/in vivo correlation by kinetic modelling. J. Drug Target. 1995; 3: 253-261.
31. Nagayasua A, Uchiyamab K, Kiwadab H. The size of liposomes: a factor which affects their targeting efficiency to tumours and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 1999; 40: 75-87.
32. Arunothayanun P, Bernard MS, Craig DQM, Uchegbu IF, Florence AT. The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether. Int. J. Pharm. 2000; 201: 7-14.
33. Hao Y, Zhao F, Yanhong NL, Li K. Studies on high encapsulation of colchicine by a niosome system. Int. J. Pharm. 2002; 244: 73-80.
34. Sahin NO. Niosomes as carrier systems, in: Mozafari MR (ed.), Nanomaterials and nanosystems for Biomedical Applications, Springer, Dordrecht, The Netherlands. 2007, pp 67-82.
35. Kreuter J. Influence of the surfactant properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotech. 2004; 4: 484-488.
36. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier, J. Drug Target. 2002; 10: 317-325.
37. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and possibilities. Pharmacol. Therap. 2004; 104: 29-45.
38. Rousselle C, Clair P, Lefacounnier J, Kaczorek M, Schermann JM, Temsaman JM. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000; 57: 679-686.